Xavier et al. have shown that the anti-HER2 nanobody binds to and inhibits ligand-driven HER2-heterodimer formation, a mechanism contributing to Trastuzumab resistance, ultimately reducing tumor resistance [91]. The gene discussed is ERBB2; the disease is neoplasm.